A Phase 4 interventional study of Nebivolol and Amlodipine in Hypertension, sponsored by Menarini International Operations Luxembourg SA. Completed at 1 site in Bulgaria. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-02-04.
Sponsored by Menarini International Operations Luxembourg SA (part of Menarini Group) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies testing nebivolol in Hypertension — none open to participants now, 1 under way, none of them phase 3. Nebivolol · Hypertension.
Among the 58 studies testing nebivolol in Hypertension, this one is the 12th largest by enrollment, is the only one that started in 2022, is one of 29 in phase 4, and was the 56th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →None of the 58 studies testing nebivolol in Hypertension is open now. The open studies under Hypertension, anywhere →
Nebivolol: first FDA approval 2007 (BYSTOLIC). What it is approved for, and how studies give it, is on its page →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 15 · Phase 4 29
First in 2001; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 301 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 70 across the 58 interventional studies. Of the 52 that completed or were terminated, 37 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 58 have an industry lead sponsor. The 10 most frequent:
This study is registered under Menarini International Operations Luxembourg SA, one of the names counted as Menarini Group. Under that name alone:
Menarini International Operations Luxembourg SA is the lead sponsor of 8 studies on the registry; none are open to participants now.
Menarini Group has 8 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 58 studies testing nebivolol in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study to assess the anti-hypertensive efficacy and safety of the extemporaneous combination of Nebivolol 5 mg in combination with Amlodipine 5 mg or AML 10 mg in lowering the sitting diastolic BP after 8 weeks of treatment inpatients with uncontrolled BP previously treated with Nebivolol (NEB) or Amlodipine (5 mg) monotherapies for at least 4 weeks.
Approximately 290 patients are planned to be screened to ensure at least 216 patients complete the run-in period and start with the assessment period.
Grade 1 - 2 hypertensive patients [BP ranging from ≥140 to ≤179 mmHg for Systolic Blood Pressure (SBP) and from ≥90 to ≤109 mmHg for Diastolic Blood Pressure (DBP)] on treatment with any Beta Blocker (BB) or Calcium Channel Blocker (CCB), including NEB (only 5 mg dosage allowed) or AML (only 5 mg dosage allowed) for at least one month prior to Visit 1 will be screened for eligibility.
Allowed CCBs at screening includes Felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nisoldipine. Patients treated with Amlodipine or Nebivolol in dosages higher than 5 mg/daily will not be eligible.
On the same day of the Screening visit, the eligible patients will enter into a run-in period of 4 weeks after screening, during which:
After 4 weeks (±2 days) of run-in period of monotherapy, the BP will be further assessed (Visit 2). Patients with uncontrolled BP levels (sitting SBP/DBP ≥130/80 mmHg) at Visit 2, with the treatment adherence (ranging between 80% to 120%) and who did tolerate the treatment will enter into the assessment period and will be assigned to the extemporaneous combination of NEB 5 mg and AML 5 mg. Patients with controlled BP levels (sitting SBP/DBP \<130/80 mmHg) and/or who do not tolerate the treatment or have an adherence range below 80% or above 120%, will be withdrawn from the study.
After 4 weeks ±2 days in the assessment period, patients BP will be further evaluated at Visit 3: patients with controlled BP levels (sitting SBP/DBP \<130/80 mmHg) will continue the same extemporaneous combination, while patients with uncontrolled BP levels will be uptitrated from extemporaneous combination NEB/AML 5/5 mg to extemporaneous combination of NEB/AML 5/10 mg for further 4 weeks.
At the end of the assessment period (8 weeks ±4 days), the patients will attend an End of Treatment Visit 4.
To correctly evaluate the additional effect of the combination therapy, the number of patients with uncontrolled BP on NEB or AML monotherapy needs to be balanced at Visit 2. In order to maintain a 1:1 ratio during the assessment period, a cap of 110 patients for each treatment arm (ie. NEB and AML) will be included at Visit 2 in order to maintain a balanced number of uncontrolled patients entering the assessment period for each drug. The evaluation will be done every 50 patients. If the rate of entrance in the assessment period for one of the 2 tested drugs will deviate more than 5%, a corrective measure will be initiated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female patients are eligible to participate if not pregnant, or not breastfeeding and if they refrain from donating or storing eggs. For females of : use of highly effective (eg. method of birth control throughout the study period and for 4 weeks after study completion defined as a method which results in a failure rate of \<1% per year) such as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MONOTHERAPY PHASE 4 weeks (Run-in from -4 week to week 0): patients will be treated with Nebivolol 5mg COMBINATION THERAPY PHASE 8 weeks (from week 0 to week 8): uncontrolled patients during Monotherapy Phase will be treated with the extemporaneous combination of Nebivolol 5mg and Amlodipine 5mg for 4 weeks (from week 0 to week 4). Amlodipine 10mg will replace Amlodipine 5mg in uncontrolled patients for further 4 weeks (from week 4 to week 8) while controlled patients with Nebivolol 5mg/Amlodipine 5mg will continue with the same therapy.
Drug: Nebivolol · Drug: Amlodipine
MONOTHERAPY PHASE 4 weeks (Run-in from -4 week to week 0): patients will be treated with Amlodipine 5mg COMBINATION THERAPY PHASE 8 weeks (from week 0 to week 8): uncontrolled patients during Monotherapy Phase will be treated with the extemporaneous combination of Nebivolol 5mg and Amlodipine 5mg for 4 weeks (from week 0 to week 4). Amlodipine 10mg will replace Amlodipine 5mg in uncontrolled patients for further 4 weeks (from week 4 to week 8) while controlled patients with Nebivolol 5mg/Amlodipine 5mg will continue with the same therapy.
Drug: Nebivolol · Drug: Amlodipine
Tablets administered orally once daily according instructions provided by Principal Investigator.
Tablets of 5mg and 10mg administered orally once daily according instructions provided by Principal Investigator.
Change in Mean Sitting Diastolic Blood Pressure (DBP) Between Visit 2 (Week 0) and Visit 4 (Week 8)
To assess the antihypertensive efficacy of the extemporaneous combination of Nebivolol (NEB) 5 mg in combination with Amlodipine (AML) 5 mg or AML 10 mg in lowering the sitting diastolic BP between Visit 2 (Week 0) and Visit 4 (Week 8) in patients with uncontrolled BP previously treated with Nebivolol or Amlodipine (5 mg) monotherapies for at least 4 weeks during run-in period.
Time frame: From Visit 2 (week 0) to Visit 4 (week 8) for a total of 8 weeks
| Milestone | Run-In Nebivolol 5mg | Run-In Amlodipine 5mg | Combination Therapy Nebivolol 5mg/ Amlodipine 5mg | Combination Therapy Nebivolol 5mg/ Amlodipine 10mg |
|---|---|---|---|---|
| Started | 143 | 158 | 0 | 0 |
| Completed | 139 | 152 | 0 | 0 |
| Not completed | 4 | 6 | 0 | 0 |
| Withdrew: Newly developed or not previously recognized exclusion criteria | 0 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 2 | 5 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 |
| Milestone | Run-In Nebivolol 5mg | Run-In Amlodipine 5mg | Combination Therapy Nebivolol 5mg/ Amlodipine 5mg | Combination Therapy Nebivolol 5mg/ Amlodipine 10mg |
|---|---|---|---|---|
| Started | 0 | 0 | 279 | 0 |
| Completed | 0 | 0 | 279 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Run-In Nebivolol 5mg | Run-In Amlodipine 5mg | Combination Therapy Nebivolol 5mg/ Amlodipine 5mg | Combination Therapy Nebivolol 5mg/ Amlodipine 10mg |
|---|---|---|---|---|
| Started | 0 | 0 | 185 | 94 |
| Completed | 0 | 0 | 182 | 94 |
| Not completed | 0 | 0 | 3 | 0 |
| Withdrew: Adverse event | 0 | 0 | 2 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 |
To assess the antihypertensive efficacy of the extemporaneous combination of Nebivolol (NEB) 5 mg in combination with Amlodipine (AML) 5 mg or AML 10 mg in lowering the sitting diastolic BP between Visit 2 (Week 0) and Visit 4 (Week 8) in patients with uncontrolled BP previously treated with Nebivolol or Amlodipine (5 mg) monotherapies for at least 4 weeks during run-in period.
| mmHg | Combination Therapy Phase Nebivolol 5mg/Amlodipine 5 or 10 mg |
|---|---|
| Change in Mean Sitting Diastolic Blood Pressure (DBP) Between Visit 2 (Week 0) and Visit 4 (Week 8) | -15.2 ± 8.32 |
Collected over From Informed Consent signature at screening visit (Visit 1) occurring 4 week previous than Baseline assessment (Week 0 - Visit 2) to last visit at Week 8 (Visit 4) for an average of 12 weeks. Furthermore patients having any ongoing Adverse Event/Serious Adverse Event at the end of the treatment (Week 8 - Visit 4), will be followed for further 2 weeks via a phone call to check about the status of the Adverse Events/Serious Adverse Events, extending the time frame to a total of 14 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nebivolo 5 mg MONOTHERAPY PERIOD | 0/143 (0%) | 0/143 (0%) | 4/143 (2.8%) |
| Amlodipine 5 mg MONOTHERAPY PERIOD | 0/158 (0%) | 0/158 (0%) | 2/158 (1.3%) |
| Nebivolo 5mg/Amlodipine 5 mg COMBINATION THERAPY PERIOD | 0/279 (0%) | 0/279 (0%) | 35/279 (12.5%) |
| Nebivolo 5mg/Amlodipine 10mg COMBINATION THERAPY PERIOD | 0/94 (0%) | 0/94 (0%) | 9/94 (9.6%) |
| Event | Nebivolo 5 mg MONOTHERAPY PERIOD | Amlodipine 5 mg MONOTHERAPY PERIOD | Nebivolo 5mg/Amlodipine 5 mg COMBINATION THERAPY PERIOD | Nebivolo 5mg/Amlodipine 10mg COMBINATION THERAPY PERIOD |
|---|---|---|---|---|
| Hepatic enzyme increasedInvestigations | 0/143 | 0/158 | 0/279 | 3/94 |
| Back painMusculoskeletal and connective tissue disorders | 0/143 | 0/158 | 3/279 | 3/94 |
| HeadacheNervous system disorders | 0/143 | 1/158 | 7/279 | 0/94 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/143 | 0/158 | 6/279 | 0/94 |
| VertigoEar and labyrinth disorders | 1/143 | 1/158 | 3/279 | 0/94 |
| ToothacheGastrointestinal disorders | 0/143 | 0/158 | 3/279 | 0/94 |
| Feeling HotGeneral disorders | 0/143 | 0/158 | 1/279 | 1/94 |
| TachycardiaCardiac disorders | 0/143 | 0/158 | 0/279 | 1/94 |
| DiarrhoeaGastrointestinal disorders | 0/143 | 0/158 | 2/279 | 1/94 |
| ErythemaSkin and subcutaneous tissue disorders | 0/143 | 0/158 | 1/279 | 1/94 |
| Age, Continuous(years) | Combination Therapy Nebivolol 5mg/ Amlodipine 5mg | Combination Therapy Nebivolol 5mg/ Amlodipine 10mg | Total |
|---|---|---|---|
| Mean | 51.5 ± 8.14 | 53.4 ± 8.02 | 52.2 ± 8.13 |
| Sex: Female, Male(Participants) | Combination Therapy Nebivolol 5mg/ Amlodipine 5mg | Combination Therapy Nebivolol 5mg/ Amlodipine 10mg | Total |
|---|---|---|---|
| Female | 99 | 45 | 144 |
| Male | 86 | 49 | 135 |
| Ethnicity (NIH/OMB)(Participants) | Combination Therapy Nebivolol 5mg/ Amlodipine 5mg | Combination Therapy Nebivolol 5mg/ Amlodipine 10mg | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 185 | 94 | 279 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2022 to primary completion in Nov 2022, 6 months.
Results were first posted in Feb 2025, 2 years 2 months after primary completion.
Of 35 industry-sponsored phase 4 interventional studies under Hypertension, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 6 months is below that.
Counting every sponsor, half of 161 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nebivolol · Amlodipine
Menarini International Operations Luxembourg SA →